AAPL297.01-1.00 (-0.34%) ▼|ABBV230.01+13.52 (+6.25%) ▲|ABT87.83-0.58 (-0.66%) ▼|ACN124.83-3.15 (-2.46%) ▼|ADBE194.90-0.26 (-0.13%) ▼|AMAT640.18+23.07 (+3.74%) ▲|AMD551.63+14.26 (+2.65%) ▲|AMGN344.72+7.12 (+2.11%) ▲|AMT176.43+0.38 (+0.22%) ▲|AMZN232.79-11.60 (-4.75%) ▼|AVGO392.13-19.22 (-4.67%) ▼|AXP338.07+0.07 (+0.02%) ▲|BA220.83-1.89 (-0.85%) ▼|BAC57.37+1.17 (+2.08%) ▲|BKNG167.77-4.01 (-2.33%) ▼|BLK1,051.74+1.65 (+0.16%) ▲|BMY54.70+0.70 (+1.30%) ▲|BNY146.44+2.81 (+1.96%) ▲|BRK-B488.69-0.77 (-0.16%) ▼|C145.67+2.61 (+1.82%) ▲|CAT1,022.28+36.46 (+3.70%) ▲|CL88.67-0.81 (-0.91%) ▼|CMCSA22.32-0.11 (-0.49%) ▼|COF200.70-0.83 (-0.41%) ▼|COP109.70+1.96 (+1.82%) ▲|COST951.35-0.10 (-0.01%) ▼|CRM150.12-1.66 (-1.09%) ▼|CSCO121.53+1.99 (+1.66%) ▲|CVS101.30+2.98 (+3.03%) ▲|CVX175.06+1.43 (+0.82%) ▲|DE598.59+9.35 (+1.59%) ▲|DHR178.19+1.02 (+0.58%) ▲|DIS102.45-1.44 (-1.39%) ▼|DUK123.52-0.34 (-0.27%) ▼|EMR150.21-0.45 (-0.30%) ▼|FDX328.78+3.80 (+1.17%) ▲|GD343.36-6.65 (-1.90%) ▼|GE355.12-2.52 (-0.70%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.87+1.11 (+0.90%) ▲|GM80.43+1.14 (+1.44%) ▲|GOOG348.78-18.68 (-5.08%) ▼|GOOGL349.68-18.35 (-4.99%) ▼|GS1,106.37+9.81 (+0.89%) ▲|HD326.62-7.66 (-2.29%) ▼|HON228.11-0.90 (-0.39%) ▼|IBM252.22+3.12 (+1.25%) ▲|INTC140.94+6.95 (+5.19%) ▲|INTU257.77-9.23 (-3.46%) ▼|ISRG402.95-3.83 (-0.94%) ▼|JNJ231.29+2.90 (+1.27%) ▲|JPM331.48+6.26 (+1.92%) ▲|KO79.53+0.14 (+0.18%) ▲|LIN516.71+4.56 (+0.89%) ▲|LLY1,102.08+3.51 (+0.32%) ▲|LMT493.60-17.35 (-3.40%) ▼|LOW214.40-7.80 (-3.51%) ▼|LRCX409.54+20.50 (+5.27%) ▲|MA484.09-5.70 (-1.16%) ▼|MCD270.10-8.51 (-3.05%) ▼|MDLZ59.51-0.61 (-1.01%) ▼|MDT79.27-0.07 (-0.09%) ▼|META563.85-13.37 (-2.32%) ▼|MMM163.22+2.62 (+1.63%) ▲|MO69.51+0.39 (+0.56%) ▲|MRK115.48+1.61 (+1.41%) ▲|MS227.09+3.92 (+1.76%) ▲|MSFT367.34-12.06 (-3.18%) ▼|MU1,211.38+77.39 (+6.82%) ▲|NEE86.08-0.67 (-0.77%) ▼|NFLX72.88-4.50 (-5.82%) ▼|NKE43.19-2.01 (-4.45%) ▼|NOW93.01-2.03 (-2.14%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.07-9.22 (-5.00%) ▼|PEP140.71-1.31 (-0.92%) ▼|PFE25.08-0.13 (-0.52%) ▼|PG147.68-2.70 (-1.80%) ▼|PLTR119.50-8.97 (-6.98%) ▼|PM173.17-5.23 (-2.93%) ▼|QCOM221.90-4.21 (-1.86%) ▼|RTX181.83-3.77 (-2.03%) ▼|SBUX100.15-0.50 (-0.50%) ▼|SCHW92.03+0.33 (+0.36%) ▲|SO93.43+0.34 (+0.37%) ▲|SPG214.57+3.24 (+1.53%) ▲|T22.10+0.09 (+0.41%) ▲|TMO464.01-0.60 (-0.13%) ▼|TMUS180.06-1.61 (-0.89%) ▼|TSLA405.05+4.56 (+1.14%) ▲|TXN332.28+9.42 (+2.92%) ▲|UBER71.43-0.21 (-0.29%) ▼|UNH406.68+5.72 (+1.43%) ▲|UNP259.91+3.03 (+1.18%) ▲|UPS107.24+2.38 (+2.27%) ▲|USB58.68+0.54 (+0.93%) ▲|V326.60-0.64 (-0.20%) ▼|VZ45.36-0.01 (-0.02%) ▼|WFC83.84+1.64 (+2.00%) ▲|WMT117.18+0.00 (+0.00%) ▲|XOM138.47+0.66 (+0.48%) ▲|AAPL297.01-1.00 (-0.34%) ▼|ABBV230.01+13.52 (+6.25%) ▲|ABT87.83-0.58 (-0.66%) ▼|ACN124.83-3.15 (-2.46%) ▼|ADBE194.90-0.26 (-0.13%) ▼|AMAT640.18+23.07 (+3.74%) ▲|AMD551.63+14.26 (+2.65%) ▲|AMGN344.72+7.12 (+2.11%) ▲|AMT176.43+0.38 (+0.22%) ▲|AMZN232.79-11.60 (-4.75%) ▼|AVGO392.13-19.22 (-4.67%) ▼|AXP338.07+0.07 (+0.02%) ▲|BA220.83-1.89 (-0.85%) ▼|BAC57.37+1.17 (+2.08%) ▲|BKNG167.77-4.01 (-2.33%) ▼|BLK1,051.74+1.65 (+0.16%) ▲|BMY54.70+0.70 (+1.30%) ▲|BNY146.44+2.81 (+1.96%) ▲|BRK-B488.69-0.77 (-0.16%) ▼|C145.67+2.61 (+1.82%) ▲|CAT1,022.28+36.46 (+3.70%) ▲|CL88.67-0.81 (-0.91%) ▼|CMCSA22.32-0.11 (-0.49%) ▼|COF200.70-0.83 (-0.41%) ▼|COP109.70+1.96 (+1.82%) ▲|COST951.35-0.10 (-0.01%) ▼|CRM150.12-1.66 (-1.09%) ▼|CSCO121.53+1.99 (+1.66%) ▲|CVS101.30+2.98 (+3.03%) ▲|CVX175.06+1.43 (+0.82%) ▲|DE598.59+9.35 (+1.59%) ▲|DHR178.19+1.02 (+0.58%) ▲|DIS102.45-1.44 (-1.39%) ▼|DUK123.52-0.34 (-0.27%) ▼|EMR150.21-0.45 (-0.30%) ▼|FDX328.78+3.80 (+1.17%) ▲|GD343.36-6.65 (-1.90%) ▼|GE355.12-2.52 (-0.70%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.87+1.11 (+0.90%) ▲|GM80.43+1.14 (+1.44%) ▲|GOOG348.78-18.68 (-5.08%) ▼|GOOGL349.68-18.35 (-4.99%) ▼|GS1,106.37+9.81 (+0.89%) ▲|HD326.62-7.66 (-2.29%) ▼|HON228.11-0.90 (-0.39%) ▼|IBM252.22+3.12 (+1.25%) ▲|INTC140.94+6.95 (+5.19%) ▲|INTU257.77-9.23 (-3.46%) ▼|ISRG402.95-3.83 (-0.94%) ▼|JNJ231.29+2.90 (+1.27%) ▲|JPM331.48+6.26 (+1.92%) ▲|KO79.53+0.14 (+0.18%) ▲|LIN516.71+4.56 (+0.89%) ▲|LLY1,102.08+3.51 (+0.32%) ▲|LMT493.60-17.35 (-3.40%) ▼|LOW214.40-7.80 (-3.51%) ▼|LRCX409.54+20.50 (+5.27%) ▲|MA484.09-5.70 (-1.16%) ▼|MCD270.10-8.51 (-3.05%) ▼|MDLZ59.51-0.61 (-1.01%) ▼|MDT79.27-0.07 (-0.09%) ▼|META563.85-13.37 (-2.32%) ▼|MMM163.22+2.62 (+1.63%) ▲|MO69.51+0.39 (+0.56%) ▲|MRK115.48+1.61 (+1.41%) ▲|MS227.09+3.92 (+1.76%) ▲|MSFT367.34-12.06 (-3.18%) ▼|MU1,211.38+77.39 (+6.82%) ▲|NEE86.08-0.67 (-0.77%) ▼|NFLX72.88-4.50 (-5.82%) ▼|NKE43.19-2.01 (-4.45%) ▼|NOW93.01-2.03 (-2.14%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.07-9.22 (-5.00%) ▼|PEP140.71-1.31 (-0.92%) ▼|PFE25.08-0.13 (-0.52%) ▼|PG147.68-2.70 (-1.80%) ▼|PLTR119.50-8.97 (-6.98%) ▼|PM173.17-5.23 (-2.93%) ▼|QCOM221.90-4.21 (-1.86%) ▼|RTX181.83-3.77 (-2.03%) ▼|SBUX100.15-0.50 (-0.50%) ▼|SCHW92.03+0.33 (+0.36%) ▲|SO93.43+0.34 (+0.37%) ▲|SPG214.57+3.24 (+1.53%) ▲|T22.10+0.09 (+0.41%) ▲|TMO464.01-0.60 (-0.13%) ▼|TMUS180.06-1.61 (-0.89%) ▼|TSLA405.05+4.56 (+1.14%) ▲|TXN332.28+9.42 (+2.92%) ▲|UBER71.43-0.21 (-0.29%) ▼|UNH406.68+5.72 (+1.43%) ▲|UNP259.91+3.03 (+1.18%) ▲|UPS107.24+2.38 (+2.27%) ▲|USB58.68+0.54 (+0.93%) ▲|V326.60-0.64 (-0.20%) ▼|VZ45.36-0.01 (-0.02%) ▼|WFC83.84+1.64 (+2.00%) ▲|WMT117.18+0.00 (+0.00%) ▲|XOM138.47+0.66 (+0.48%) ▲|
21 C
New York
Tuesday, June 23, 2026

Tag: public health

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT
Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT

DIGITAL HEALTH LEADER JMIR PUBLICATIONS ANNOUNCES ITS 2025 IMPACT FACTOR RESULTS

The JMIR Publications portfolio of journals now includes 21 journals with a Journal Impact Factor, with several journals achieving significant year-over-year increases and special distinctions. TORONTO,...

Gene Solutions Strengthens China Footprint with Strategic Partnerships in Precision Oncology

BEIJING, June 20, 2025 /PRNewswire/ -- Gene Solutions announces the signing of two strategic Memoranda of Understanding (MOUs) with ZaoDx and Xiong'an MagicBiotech Co., Ltd....

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Cochlear celebrates 30 Years in China and the launch of the world’s first and only smart hearing implant system

The new Cochlear™ Nucleus® Nexa™ System is the first and only hearing implant featuring internal memory and upgradeable firmware.1+This year marks the 30-year anniversary since...

Biological Safety Cabinets Market to Reach USD 448.4 Million by 2032, Driven by Rising Biosafety Standards and Research Demand

PUNE, India, June 19, 2025 /PRNewswire/ -- According to a recent market analysis published by Credence Research Inc., the global Biological Safety Cabinets (BSCs) market...

RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and The University of Manchester Develop First Risk Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma

Research Published in NEJM Evidence and presented at the International Conference on Malignant Lymphoma NEW BRUNSWICK, N.J. and BOSTON, June 19, 2025 /PRNewswire/ -- Researchers from...

Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans

HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased...

Elton John AIDS Foundation launches pilot schemes to accelerate access to Pre-Exposure Prophylaxis (PrEP) and reduce new HIV transmissions in England

LONDON, June 19, 2025 /PRNewswire/ -- The Elton John AIDS Foundation, together with Fast-Track Cities, Gilead Sciences and ViiV Healthcare, is investing over £1 million...

Nuvalent Appoints Christy Oliger to Board of Directors

CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,...

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with...

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors

MassChallenge and The Food & Nutrition Innovation Institute at the Friedman School at Tufts University Announce Strategic Collaboration to Advance Nutrition and Health Innovation

BOSTON, June 18, 2025 /PRNewswire/ -- MassChallenge, the global network for innovators accelerating startups solving massive challenges, and the Food & Nutrition Innovation Institute,...

Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®

The Oligonucleotide Synthesis Market is poised for robust growth, fueled by advancements in personalized medicine, molecular diagnostics, and genomics research. However, high production costs, regulatory...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPublic health